ValiRx plc (AIM:VAL)

Market Cap	2.25M
Revenue (ttm)	49.78K
Net Income (ttm)	-1.92M
Shares Out	374.35M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	739,426
Average Volume	3,884,840
Open	0.6350
Previous Close	0.6000
Day's Range	0.5600 - 0.6500
52-Week Range	0.3750 - 3.1000
Beta	-0.47
RSI	67.77
Earnings Date	Jul 3, 2025

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 16
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.